Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.

Joyce AT, Gandra SR, Fox KM, Smith TW, Pill MW.

J Med Econ. 2014 Jan;17(1):1-10. doi: 10.3111/13696998.2013.856314. Epub 2013 Oct 31.

PMID:
24131136
2.

A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in hypertensive patients without prior cardiovascular disease.

Foody JM, Joyce AT, Jeffers BW, Liu LZ, Benner JS.

Am J Ther. 2011 Mar-Apr;18(2):110-6. doi: 10.1097/MJT.0b013e3181cf12d2.

PMID:
20216383
3.

Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients.

Schumock GT, Andress DL, Marx SE, Sterz R, Joyce AT, Kalantar-Zadeh K.

Nephron Clin Pract. 2009;113(1):c54-61. doi: 10.1159/000228076. Epub 2009 Jul 10.

4.

Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA.

Joyce AT, Smith P, Khandker R, Melin JM, Singh A.

J Rheumatol. 2009 Apr;36(4):743-52. doi: 10.3899/jrheum.080670. Epub 2009 Feb 17.

PMID:
19228658
5.

Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients.

Schumock GT, Andress D, E Marx S, Sterz R, Joyce AT, Kalantar-Zadeh K.

Curr Med Res Opin. 2008 Nov;24(11):3037-48. doi: 10.1185/03007990802437943 . Epub 2008 Oct 2.

PMID:
18826748
6.

A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in diabetic patients without prior cardiovascular disease.

Foody JM, Joyce AT, Jeffers BW, Liu LZ, Benner JS.

Diabetes Res Clin Pract. 2008 Oct;82(1):e13-5. doi: 10.1016/j.diabres.2008.07.019. Epub 2008 Sep 6.

PMID:
18774618
7.

Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.

Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.

Curr Med Res Opin. 2008 Jul;24(7):1987-2000. doi: 10.1185/03007990802203279 . Epub 2008 Jun 4. Erratum in: Curr Med Res Opin. 2010 Mar;26(3):631.

PMID:
18554430
8.

Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.

Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.

Clin Ther. 2008 Jan;30(1):195-205. doi: 10.1016/j.clinthera.2008.01.003.

PMID:
18343257
9.

Burden of illness among commercially insured patients with Alzheimer's disease.

Joyce AT, Zhao Y, Bowman L, Flynn JA, Carter CT, Ollendorf DA.

Alzheimers Dement. 2007 Jul;3(3):204-10. doi: 10.1016/j.jalz.2007.04.373.

PMID:
19595939
10.

Effect of initial ziprasidone dose on length of therapy in schizophrenia.

Joyce AT, Harrison DJ, Loebel AD, Carter CT, Ollendorf DA.

Schizophr Res. 2006 Apr;83(2-3):285-92. Epub 2006 Mar 20.

PMID:
16545543
11.

Impact of atypical antipsychotics on outcomes of care in schizophrenia.

Joyce AT, Harrison DJ, Loebel AD, Ollendorf DA.

Am J Manag Care. 2005 Sep;11(8 Suppl):S254-61.

12.

End-stage renal disease-associated managed care costs among patients with and without diabetes.

Joyce AT, Iacoviello JM, Nag S, Sajjan S, Jilinskaia E, Throop D, Pedan A, Ollendorf DA, Alexander CM.

Diabetes Care. 2004 Dec;27(12):2829-35.

PMID:
15562193

Supplemental Content

Loading ...
Support Center